Biophytis S.A. (ALBPS.PA)
EUR 0.16
(-2.95%)
EUR 0.16
(-2.95%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 8.27 Million EUR | -31.8% |
| 2022 | 12.12 Million EUR | -21.14% |
| 2021 | 15.37 Million EUR | 69.06% |
| 2020 | 9.09 Million EUR | -40.34% |
| 2019 | 15.24 Million EUR | 85.94% |
| 2018 | 8.19 Million EUR | 709.38% |
| 2017 | 1.01 Million EUR | -6.98% |
| 2016 | 1.08 Million EUR | 35.65% |
| 2015 | 802.79 Thousand EUR | 10.78% |
| 2014 | 724.67 Thousand EUR | 56.44% |
| 2013 | 463.22 Thousand EUR | -20.2% |
| 2012 | 580.46 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 9.54 Million EUR | 1.71% |
| 2024 Q1 | 9.54 Million EUR | 15.44% |
| 2023 FY | 8.27 Million EUR | -31.8% |
| 2023 Q1 | 12.65 Million EUR | 4.37% |
| 2023 Q2 | 9.58 Million EUR | -24.28% |
| 2023 Q4 | 8.27 Million EUR | 0.66% |
| 2023 Q3 | 8.21 Million EUR | -14.26% |
| 2022 Q2 | 14.41 Million EUR | -22.74% |
| 2022 Q4 | 12.12 Million EUR | -15.2% |
| 2022 FY | 12.12 Million EUR | -21.14% |
| 2022 Q3 | 14.3 Million EUR | -0.78% |
| 2022 Q1 | 18.65 Million EUR | 21.31% |
| 2021 Q3 | 17.33 Million EUR | 18.86% |
| 2021 FY | 15.37 Million EUR | 69.06% |
| 2021 Q1 | 18.16 Million EUR | 99.73% |
| 2021 Q2 | 14.58 Million EUR | -19.71% |
| 2021 Q4 | 15.37 Million EUR | -11.3% |
| 2020 Q3 | 15.05 Million EUR | 32.56% |
| 2020 Q1 | 11.35 Million EUR | -18.69% |
| 2020 Q2 | 11.35 Million EUR | 0.0% |
| 2020 Q4 | 9.09 Million EUR | -39.58% |
| 2020 FY | 9.09 Million EUR | -40.34% |
| 2019 FY | 15.24 Million EUR | 85.94% |
| 2019 Q3 | 16.45 Million EUR | 59.83% |
| 2019 Q1 | 10.55 Million EUR | 29.44% |
| 2019 Q4 | 13.96 Million EUR | -15.13% |
| 2019 Q2 | 10.29 Million EUR | -2.44% |
| 2018 Q4 | 8.15 Million EUR | 0.0% |
| 2018 FY | 8.19 Million EUR | 709.38% |
| 2018 Q3 | 8.15 Million EUR | 488.24% |
| 2018 Q2 | 1.38 Million EUR | 0.0% |
| 2018 Q1 | - EUR | -100.0% |
| 2017 Q4 | 1.01 Million EUR | 4.87% |
| 2017 FY | 1.01 Million EUR | -6.98% |
| 2017 Q1 | 1.02 Million EUR | -6.15% |
| 2017 Q2 | 1.06 Million EUR | 4.5% |
| 2017 Q3 | 966 Thousand EUR | -9.55% |
| 2016 Q1 | 452 Thousand EUR | -43.7% |
| 2016 Q4 | 1.08 Million EUR | 4.21% |
| 2016 FY | 1.08 Million EUR | 35.65% |
| 2016 Q3 | 1.04 Million EUR | 111.11% |
| 2016 Q2 | 495 Thousand EUR | 9.51% |
| 2015 Q3 | 759 Thousand EUR | -70.25% |
| 2015 Q1 | 2.55 Million EUR | 252.06% |
| 2015 FY | 802.79 Thousand EUR | 10.78% |
| 2015 Q4 | 802.79 Thousand EUR | 5.77% |
| 2015 Q2 | 2.55 Million EUR | 0.0% |
| 2014 Q3 | 724.67 Thousand EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 Q4 | 724.67 Thousand EUR | 0.0% |
| 2014 FY | 724.67 Thousand EUR | 56.44% |
| 2013 FY | 463.22 Thousand EUR | -20.2% |
| 2012 FY | 580.46 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -143.953% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 85.089% |
| Adocia SA | 13.08 Million EUR | 36.812% |
| Aelis Farma SA | 4.03 Million EUR | -104.804% |
| Advicenne S.A. | 17.42 Million EUR | 52.539% |
| genOway Société anonyme | 7.23 Million EUR | -14.331% |
| IntegraGen SA | 1.12 Million EUR | -635.284% |
| Medesis Pharma S.A. | 1.2 Million EUR | -589.167% |
| Neovacs S.A. | 650 Thousand EUR | -1172.308% |
| NFL Biosciences SA | 62.17 Thousand EUR | -13201.38% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -89.831% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -204.398% |
| Sensorion SA | 2.86 Million EUR | -188.275% |
| Theranexus Société Anonyme | 3.64 Million EUR | -127.009% |
| TME Pharma N.V. | 1.16 Million EUR | -609.262% |
| Valbiotis SA | 6.87 Million EUR | -20.238% |
| TheraVet SA | 1.15 Million EUR | -613.013% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 8.091% |
| DBV Technologies S.A. | 13.01 Million USD | 36.476% |
| Genfit S.A. | 70.17 Million EUR | 88.216% |
| GeNeuro SA | 7.73 Million EUR | -6.878% |
| Innate Pharma S.A. | 39.89 Million EUR | 79.27% |
| Inventiva S.A. | 37.4 Million EUR | 77.892% |
| MaaT Pharma SA | 14.07 Million EUR | 41.243% |
| MedinCell S.A. | 58.96 Million EUR | 85.974% |
| Nanobiotix S.A. | 50.56 Million EUR | 83.645% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 81.944% |
| Poxel S.A. | 46.9 Million EUR | 82.367% |
| GenSight Biologics S.A. | 18.42 Million EUR | 55.123% |
| Transgene SA | 1.25 Million EUR | -557.916% |
| Valneva SE | 208.81 Million EUR | 96.04% |